Clinical trial · Observational
PET Guided Bone Marrow Biopsy vs Trephine Bone Marrow Biopsy
Role of FDG PET/CT Guided Bone Marrow Biopsy vs. Conventional Bone Marrow Trephine Biopsy for Assessing the Bone Marrow Infiltration in Newly Diagnosed Lymphoma
NCT05251168CI-TRIAL-00056695completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Newly diagnosed lymphoma patients were recruited for FDG PET/CT and PET/CT guided bone marrow biopsy. All the patients also underwent routine bone marrow sampling from the posterior superior iliac spine.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Marrow Neoplasm | Bone Marrow Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET Guided Bone Marrow Biopsy | Procedure | — | UNRESOLVED |
| Trephine Bone Marrow Biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Comparison results of PET guided bone marrow biopsy with trephine bone marrow biopsy
- timeFrame
- three months
- description
- The final diagnosis of bone marrow infiltration was based on the pathology findings of trephine bone marrow biopsy and FDG PET/CT targeted bone marrow biopsy. The diagnostic accuracy (in percentage) of FDG PET/CT guided metabolic bone marrow biopsy was compared with the accuracy (in percentage) of trephine bone marrow biopsy with respect to final diagnosis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Newly diagnosed cases of lymphoma (both HL and NHL). 2. Hypermetabolic bone marrow lesions on staging 18F-FDG PET/CT, which are accessible for biopsy. 3. Aged between 18 -80 years. 4. Informed consent prior to the procedure. Exclusion Criteria: 1. Previously treated/relapsed lymphoma. 2. Initiation of therapy (chemotherapy, radiation therapy) and/or hematopoietic growth factor injections before 18F-FDG PET/CT or BMTB. 3. Patients who underwent a prior BMTB to evaluate the role of BMI. 4. Patients with pre-existing bleeding diatheses like hemophilia, coagulopathy, INR \> 1.2 and platelet counts \< 50,000/mm3, 5. Patients who refuse to provide informed consent. 6. No 18F FDG avid skeletal lesions. 7. Pregnant/Lactating female patients. 8. Non-cooperative patients.
References
Publications (1)
- DERIVEDMahdi RA, Dasagrathi V, Kumar R, Singh H, Mittal BR, Prakash G, Malhotra P, Bal A, Naseem S. Comparison of automated robotic arm-assisted PET/computed tomography-guided metabolic bone marrow biopsy with conventional bone marrow trephine biopsy for evaluating bone marrow infiltration in newly diagnosed lymphoma. Nucl Med Commun. 2026 Sep 1;47(9):1102-1110. doi: 10.1097/MNM.0000000000002170. Epub 2026 May 6. PMID 42087722